Upgrade to SI Premium - Free Trial

Iovance Biotherapeutics (IOVA)

14.83 +0.73 (5.18%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/7/24)

Latest Headlines

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) March 22, 2024 5:30 PM - Globe NewsWire Form SC 13D/A IOVANCE BIOTHERAPEUTICS, Filed by: Quogue Capital LLC March 19, 2024 5:20 PM - SEC Filing Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Piper Sandler March 14, 2024 10:37 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $26 at Truist Securities March 7, 2024 8:59 AM - StreetInsider Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 04 Filed by: GRAF FINCKENSTEIN FRIEDRICH March 6, 2024 6:21 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 04 Filed by: Vogt Frederick G March 6, 2024 6:19 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 04 Filed by: BILINSKY IGOR March 6, 2024 6:18 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: YARNO WENDY L March 5, 2024 5:58 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Rothbaum Wayne P. March 5, 2024 5:57 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Vogt Frederick G March 5, 2024 5:56 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Maynard Ryan D March 5, 2024 5:56 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: WEISER MICHAEL March 5, 2024 5:55 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: MCPEAK MERRILL A March 5, 2024 5:54 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Dukes Iain D. March 5, 2024 5:53 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: GRAF FINCKENSTEIN FRIEDRICH March 5, 2024 5:53 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: BILINSKY IGOR March 5, 2024 5:53 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Bellemin Jean-Marc March 5, 2024 5:52 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 01 Filed by: Countouriotis Athena March 5, 2024 5:51 PM - SEC Filing Form 8-K IOVANCE BIOTHERAPEUTICS, For: Mar 04 March 4, 2024 8:01 AM - SEC Filing Iovance Biotherapeutics (IOVA) Announces FDA Hold Lifted on IOV-LUN-202 Registrational Trial March 4, 2024 6:30 AM - StreetInsider Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer March 4, 2024 6:30 AM - StreetInsider Iovance Biotherapeutics to Present at Upcoming Conferences March 2, 2024 6:07 AM - Globe NewsWire Form SC 13G IOVANCE BIOTHERAPEUTICS, Filed by: PERCEPTIVE ADVISORS LLC March 1, 2024 7:10 PM - SEC Filing Iovance Biotherapeutics to Present at Upcoming Conferences March 1, 2024 5:00 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $25 at Wells Fargo March 1, 2024 4:57 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 28 February 29, 2024 7:32 AM - SEC Filing Iovanace Biotherapeutics (IOVA) PT Raised to $21 at Goldman Sachs February 29, 2024 6:05 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $22 at Barclays February 29, 2024 3:42 AM - StreetInsider Form 10-K IOVANCE BIOTHERAPEUTICS, For: Dec 31 February 28, 2024 5:33 PM - SEC Filing Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 2c February 28, 2024 4:19 PM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 28 February 28, 2024 4:07 PM - SEC Filing Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates  February 28, 2024 4:01 PM - Globe NewsWire Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 22 February 22, 2024 4:54 PM - SEC Filing Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 February 22, 2024 8:45 AM - Globe NewsWire Form 424B5 IOVANCE BIOTHERAPEUTICS, February 21, 2024 4:47 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Feb 20 Filed by: MCPEAK MERRILL A February 20, 2024 7:53 PM - SEC Filing Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 20 February 20, 2024 5:23 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Feb 20 Filed by: Dukes Iain D. February 20, 2024 4:22 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Feb 20 Filed by: Rothbaum Wayne P. February 20, 2024 4:12 PM - SEC Filing Iovance Biotherapeutics (IOVA) price targets raised following FDA accelerated approval February 20, 2024 1:59 PM - StreetInsider WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma February 20, 2024 8:01 AM - PR NewsWire Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Piper Sandler February 20, 2024 7:31 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $22 at Wells Fargo February 20, 2024 7:11 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $32 at H.C. Wainwright February 20, 2024 6:40 AM - StreetInsider Iovance Biotherapeutics (IOVA) Prices 23M Share Offering at $9.15/sh February 20, 2024 6:30 AM - StreetInsider Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock February 20, 2024 6:30 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $26 at Baird February 20, 2024 6:24 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 16 February 20, 2024 6:05 AM - SEC Filing Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Goldman Sachs February 20, 2024 4:56 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $25 at JMP Securities February 20, 2024 3:00 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $24 at Jefferies February 19, 2024 10:24 AM - StreetInsider Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) February 16, 2024 5:30 PM - Globe NewsWire Iovance Biotherapeutics (IOVA) CEO: CEO: AMTAGVI to Sell in US at $550,000 Per Patient February 16, 2024 4:33 PM - StreetInsider Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 February 16, 2024 3:38 PM - Globe NewsWire Iovance's (IOVA) AMTAGVI (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma February 16, 2024 3:22 PM - StreetInsider Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma February 16, 2024 3:19 PM - Globe NewsWire Iovance Biotherapeutics (IOVA) Halted, News Pending February 16, 2024 2:56 PM - StreetInsider Iovance Biotherapeutics (IOVA) call put ratio 6.1 calls to 1 put February 16, 2024 4:31 AM - StreetInsider Iovance Biotherapeutics (IOVA) call put ratio 5.2 calls to 1 put February 15, 2024 5:04 AM - StreetInsider Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: PERCEPTIVE ADVISORS LLC February 14, 2024 4:29 PM - SEC Filing Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Point72 Asset Management, L.P. February 14, 2024 6:17 AM - SEC Filing Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: VANGUARD GROUP INC February 13, 2024 5:13 PM - SEC Filing Iovance Biotherapeutics (IOVA) call put ratio 5.9 calls to 1 put February 12, 2024 5:33 AM - StreetInsider Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: MHR FUND MANAGEMENT LLC February 9, 2024 5:41 PM - SEC Filing Iovance Biotherapeutics (IOVA) calls more active than puts February 6, 2024 3:58 AM - StreetInsider Iovance Biotherapeutics (IOVA) option IV into melanoma PDUFA February 1, 2024 4:11 AM - StreetInsider Iovance Biotherapeutics (IOVA) call put ratio 3.5 calls to 1 put with focus on March 11 calls January 31, 2024 1:18 PM - StreetInsider Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: BlackRock Inc. January 26, 2024 11:53 AM - SEC Filing Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jan 25 January 26, 2024 6:03 AM - SEC Filing Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP January 25, 2024 10:50 AM - SEC Filing Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) January 19, 2024 5:15 PM - Globe NewsWire Form 4 IOVANCE BIOTHERAPEUTICS, For: Jan 16 Filed by: Vogt Frederick G January 18, 2024 6:10 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Jan 16 Filed by: GRAF FINCKENSTEIN FRIEDRICH January 18, 2024 6:09 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Jan 16 Filed by: BILINSKY IGOR January 18, 2024 6:08 PM - SEC Filing Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jan 08 January 8, 2024 5:04 PM - SEC Filing Full Article List